Evidence map›Paper›PMID 30619759›Full record

ArticleFrontiers in oncology2018

Phage Ligands for Identification of Mesenchymal-Like Breast Cancer Cells and Cancer-Associated Fibroblasts.

Kelvin M Jones, Balasubramanyam Karanam, Jacqueline Jones-Triche, Maninder Sandey, Henry J Henderson, Rajeev S Samant, Samuel Temesgen, Clayton Yates, Deepa Bedi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Targeting breast cancer: the promise of phage-based nanomedicines.Breast cancer research and treatment · 2025
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kelvin M JonesDepartment of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL, United States.
Balasubramanyam KaranamDepartment of Biology, Center for Cancer Research, Tuskegee University, Tuskegee, AL, United States.
Jacqueline Jones-TricheDepartment of Biology and Environmental Sciences, Troy University, Troy, AL, United States.
Maninder SandeyDepartment of Pathobiology, Auburn University, Auburn, AL, United States.
Henry J HendersonDepartment of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL, United States.
Rajeev S SamantDepartment of Pathobiology, The University of Alabama at Birmingham, Birmingham, AL, United States.
Samuel TemesgenDepartment of Pathobiology, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL, United States.
Clayton YatesDepartment of Biology, Center for Cancer Research, Tuskegee University, Tuskegee, AL, United States.
Deepa BediDepartment of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL, United States.
Tuskegee University · USAuburn University · USTroy University · USUniversity of Alabama at Birmingham · US

Funding

Tuskegee University Center for Biomedical Research/ Research Centers at Minority InstitutionsU54MD007585 · NIMHD · TUSKEGEE UNIVERSITY · PI Jason Anthony White · 2017 to 2026
$29.4M
TRAINING AND CAREER DEVELOPMENTU54CA118948 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UPENDER MANNE · 2005 to 2026
$26.6M
Research Training & Career Development ProgramU54CA118638 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI Desiree Avia Rivers · 2005 to 2026
$22.7M
Research Education CoreU54CA118623 · NCI · TUSKEGEE UNIVERSITY · PI Vivian L Carter, TIMOTHY TURNER · 2005 to 2026
$20.2M
Phage Display to Identify Epithelial to Mesenchymal Transitioned (EMT) Breast Cancer CellsSC2CA211028 · NCI · TUSKEGEE UNIVERSITY · PI BEDI, DEEPA · 2016 to 2018
$441k
NCI NIH HHS SC2 CA211028NCI NIH HHS U54 CA118623NCI NIH HHS U54 CA118638NCI NIH HHS U54 CA118948NIMHD NIH HHS U54 MD007585
6 · The paper itself

Abstract

Epithelial to mesenchymal transition (EMT) is believed to be crucial for primary tumors to escape their original residence and invade and metastasize. To properly define EMT, there is a need for ligands that can identify this phenomenon in tumor tissue and

Indexed as

breast cancercancer-associated fibroblastsEMTfibroblastsPhage display

Identifiers

PMID30619759
PMCPMC6304394
OpenAlexW2904206624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.